Zobrazeno 1 - 10
of 188
pro vyhledávání: '"J-Matthias Graf von der Schulenburg"'
Autor:
Ana Babac, Martin Frank, Frédéric Pauer, Svenja Litzkendorf, Daniel Rosenfeldt, Verena Lührs, Lisa Biehl, Tobias Hartz, Holger Storf, Franziska Schauer, Thomas O. F. Wagner, J-Matthias Graf von der Schulenburg
Publikováno v:
BMC Health Services Research, Vol 18, Iss 1, Pp 1-14 (2018)
Abstract Background Rare diseases are, by definition, very serious and chronic diseases with a high negative impact on quality of life. Approximately 350 million people worldwide live with rare diseases. The resulting high disease burden triggers hea
Externí odkaz:
https://doaj.org/article/b75454208e5643aa8a23af54ee966039
Autor:
Svenja Litzkendorf, Martin Frank, Ana Babac, Daniel Rosenfeldt, Franziska Schauer, Tobias Hartz, J.-Matthias Graf von der Schulenburg
Publikováno v:
BMC Public Health, Vol 20, Iss 1, Pp 1-14 (2020)
Abstract Background Finding reliable information on one of more than 7000 rare diseases is a major challenge for those affected. Since rare diseases are defined only by the prevalence criterion, a multitude of heterogeneous diseases are included. Com
Externí odkaz:
https://doaj.org/article/20f799d1b02744f896a286975b6c5e8b
Publikováno v:
Health Economics Review, Vol 9, Iss 1, Pp 1-17 (2019)
Abstract Background Since the implementation of the Regulation on Patient Integration (2003), the Act on the Reorganization of the Pharmaceutical Market (2011), and the Patient Rights Law (2013), the inclusion of patient perspectives has been further
Externí odkaz:
https://doaj.org/article/a02c93154c8f4c40afc9cbbe9ba45d14
Insurance today is a global economic colossus and a fixture in the developed countries of the world. Dependant upon a considerable dose of moral exhortation and enlightened appeal, the insurance industry has become a pervasive agent of social and eco
Autor:
Thomas R. Staab, Miriam Walter, Sonja Mariotti Nesurini, Charalabos-Markos Dintsios, J.-Matthias Graf von der Schulenburg, Volker E. Amelung, Jörg Ruof
Publikováno v:
Health Economics Review, Vol 8, Iss 1, Pp 1-11 (2018)
Abstract Background According to the AMNOG act, the German Federal Joint Committee (G-BA) determines the additional benefit of new medicines as a basis for subsequent price negotiations. Pharmaceutical companies may withdraw their medications from th
Externí odkaz:
https://doaj.org/article/b0233d39cbbf4519bd29290918586e0e
Publikováno v:
Health Economics Review, Vol 11, Iss 1, Pp 1-2 (2021)
Externí odkaz:
https://doaj.org/article/23ae21cd8d4e4743974b6fb2c091e3a2
Publikováno v:
Health and Quality of Life Outcomes, Vol 15, Iss 1, Pp 1-13 (2017)
Abstract Background The EuroQol Group has extended the severity levels of the EQ-5D from three to five (EQ-5D-5L). There are valuation studies worldwide planned in order to convert the EQ-5D-5L health states into a single preference-based summary sco
Externí odkaz:
https://doaj.org/article/1683089d79bd4be6b3d14eba081ad42c
Publikováno v:
The European Journal of Health Economics. 24:803-816
This paper examines dividend policy issues in the European pharmaceutical industry. This sector is of particular interest because of the high research and development expenditures and the associated risks characterizing the business models of many fi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::738aed418f35b115b6dd0b46906cfac5
https://doi.org/10.1007/s10198-022-01510-5
https://doi.org/10.1007/s10198-022-01510-5
Autor:
Michael Thomas, Manfred Dietel, Silke Zaun, Monika Serke, Christian Schumann, Joerg Mezger, J.-Matthias Graf von der Schulenburg, Juergen R. Fischer, Wilfried Ernst Erich Eberhardt, Peter Schirmacher, Wolfgang Schuette
EPI-14-1149 . EGFR mutation type by tissue source tested
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d831f9da206095ed155297cf9641c7e
https://doi.org/10.1158/1055-9965.22438029
https://doi.org/10.1158/1055-9965.22438029
Autor:
Michael Thomas, Manfred Dietel, Silke Zaun, Monika Serke, Christian Schumann, Joerg Mezger, J.-Matthias Graf von der Schulenburg, Juergen R. Fischer, Wilfried Ernst Erich Eberhardt, Peter Schirmacher, Wolfgang Schuette
Supplemental Table S3. Tissue source and testing method used for EGFR mutation analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e759855dc2d9e106338016ea02a4610
https://doi.org/10.1158/1055-9965.22438023.v1
https://doi.org/10.1158/1055-9965.22438023.v1